Looking Back on the 1st Year of the GFATM New Funding Model

In May 2014, countries submitted concept notes in the first review window of the new approach to grant-making approved by the Board for full implementation just two months earlier. By the end of the year, the Technical Review Panel (TRP) had reviewed 111 concept notes, approximately 43% of all expected country submissions for the 2014-2016 allocation period and representing nearly … Read More

Nisa PatelLooking Back on the 1st Year of the GFATM New Funding Model

New Private Sector Opportunities Approved, Governance Reforms Launched at Global Fund 32nd Board Meeting

November 18 – 21, 2014 | Montreux, Switzerland The Global Fund Board met for its 32nd Board meeting in Montreux, Switzerland from November 18-21.  Over the course of the meetings, the Board approved major decisions including: amendments allowing the private sector to make restricted financial contributions against unfunded portions of approved country grant requests reforms to enhance Board and committee … Read More

Nisa PatelNew Private Sector Opportunities Approved, Governance Reforms Launched at Global Fund 32nd Board Meeting

Recent Events and GF Results Highlight Global Progress Against the Three Diseases

On World AIDS Day, the Global Fund announced key programmatic results from Global Fund-supported grant programs in 2014, showing steady gains across indicators, including a 20% scale-up in people on anti-retroviral therapy, a 24% scale-up in bed net distribution, and a 39% scale up in people treated for multi-drug-resistant TB since 2013. Although the results indicate positive signs of progress, … Read More

Nisa PatelRecent Events and GF Results Highlight Global Progress Against the Three Diseases

Meet the PSD: Luisa Engel and Dr. Gerhard Hesse

Luisa Engel Director of External Relations, (RED) Dr. Gerhard Hesse Head of Global Partnering / Vector Control, Bayer How did (RED) become involved with the Global Fund? The Global Fund is part of (RED)’s DNA. The Fund was established in 2002 but it was struggling to get funding from the corporate sector and because its charter is to be a public-private partnership, it was … Read More

Nisa PatelMeet the PSD: Luisa Engel and Dr. Gerhard Hesse

PSD Elections for 2015-2017 Board Member and Alternate Board Member: Call for Applications

The Private Sector Delegation (PSD) to the Board of the Global Fund to Fight AIDS, Tuberculosis and Malaria is now accepting applications for Board Member and Alternate Board Member positions for the upcoming 2015-2017 term. The PSD Board Member and Alternate Board Member will represent the private sector as a voting constituency to the Global Fund’s governance board for a … Read More

Nisa PatelPSD Elections for 2015-2017 Board Member and Alternate Board Member: Call for Applications

Guide to 2014 UN General Assembly Side Events

The 69th session of the United Nations General Assembly (UNGA) will convene the week of September 22nd in New York City, drawing together government, business and health leaders from around the world. A prominent theme this year will be the Millennium Development Goals (MDGs)—eight targets that the global health community is working toward achieving by 2015, and the new Post-2015 Sustainable … Read More

Nisa PatelGuide to 2014 UN General Assembly Side Events

IAC 2014 Highlights Private Sector Action on AIDS

July 20-25, 2014 | Melbourne, Australia The 20th International AIDS Conference (IAC), themed Stepping up the Pace, presented new scientific knowledge and many opportunities for structured dialogue on the major issues facing the global response to HIV. The conference also provided an opportunity to highlight the HIV epidemic in the Asia-Pacific region, with high-level speakers including former U.S. President Bill … Read More

Nisa PatelIAC 2014 Highlights Private Sector Action on AIDS

Meet the PSD: Erika Satterwhite & René Cazetien

Erika Satterwhite Manager, Global Policy, Mylan René Cazetien Associate Vice President of Operations, Access to Medicines, Sanofi How did Mylan become involved with the Global Fund? Mylan’s decision to join the PSD Advisory Group is rooted in the company’s desire to provide the often-missing generic manufacturer’s perspective in shaping good public policy around the Global Fund’s efforts to combat HIV/AIDS, TB, … Read More

Nisa PatelMeet the PSD: Erika Satterwhite & René Cazetien

UKRAINE: Dealing with the Highest Dual Burden of TB and HIV in Europe

Over the last year, Ukraine has made notable progress in the fight against HIV. HIV incidence in Eastern Europe, unlike other regions in the world, has been on the increase and Ukraine has the most severe HIV and TB epidemics in Europe. The Global Fund has invested over $362 million in Ukraine, $320 million of which targeted HIV programs. These … Read More

Nisa PatelUKRAINE: Dealing with the Highest Dual Burden of TB and HIV in Europe

MYLAN: Eliminating Mother-to-Child Transmission of HIV in Nigeria

As one of the world’s leading manufacturers of generics, Mylan supplies high-quality, low-cost treatments to 40% of people currently on antiretroviral therapy (ARVs). Now, through a partnership announced on World AIDS Day 2013, Mylan aims to expand access to ARV treatment. A partnership between Mylan, the Elton John AIDS Foundation and the Business Leadership Council (BLC) in Nigeria aims to catalyze … Read More

Nisa PatelMYLAN: Eliminating Mother-to-Child Transmission of HIV in Nigeria